Table 3 Expression of phosphorylated MAPK in flat-depressed and protruding neoplasias compared with clinicopathological and molecular characteristics

From: BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias

 

Expression of p-MAPK

 

FDNs ( N =46)

 

PNs ( N =55)

 
 

Type A

Type B/C

P -value

Type A

Type B/C

P -value

Location

 Left-c and rectum

3

14

0.4893*

13

12

0.5514**

 Right-c

9

20

 

18

12

 

Size

 <10 mm

3

11

0.7294*

16

5

0.0265*

 ⩾10 mm

9

23

 

15

19

 

Macroscopic type

 Flat

9

18

0.3071*

NA

  

 Depressed

3

16

    

Histology

 Adenoma

11

18

0.0338*

23

19

0.7561*

 Dukes' A carcinoma

1

16

 

8

5

 

BRAF mutation

 Mut+

2

2

0.2758*

0

0

NA

 Mut−

10

32

 

31

24

 

KRAS mutation

 Mut+

0

0

NA

4

10

0.0272*

 Mut−

12

34

 

27

14

 

MSI a

 MSS/MSI-L

11

26

0.6532*

30

19

>0.999*

 MSI-H

1

6

 

1

0

 
  1. Evaluating systems for immunohistochemical staining for p-MAPK are described in Materials and Methods. aThe numbers for MSI reflect the numbers of cases among the informative cases. p-MAPK=phosphorylated mitogen-activated protein kinase; FDNs=flat and depressed neoplasias; PNs=protruding neoplasias; Left-c=sigmoid and descending colon; Right-c=transverse, ascending colon, and cecum; Mut+=presence of mutation; Mut−=absence of mutation; MSI=microsatellite instability; MSS=microsatellite stable; MSI-L=low-frequency MSI; MSI-H=high-frequency MSI; NA=not applicable. *P-value calculated by Fisher's exact test; **P-value calculated by χ2 test.
Back to article page